The Trump administration withdrew its nomination of White House health aide Heidi Overton to lead the Food and Drug Administration Tuesday amid opposition from Senate Republicans, a White House official confirmed to MS NOW.
The official did not provide a reason for the withdrawal, but the move comes after Sen. Bill Cassidy, R-La., a physician and chair of the Senate Health Education, Labor and Pensions Committee, said last week that he and other GOP committee members were “undecided” about Overton.
Cassidy previously said he was concerned about Overton’s “lack of managerial experience” and her role in an executive order that recommended upending the childhood vaccine schedule. He said that her involvement “calls into question her commitment to standing up for sound science and protecting children’s health.”
Axios first reported the withdrawal Tuesday night, less than a day before the committee was scheduled to vote on advancing Overton’s nomination.
In a statement on X, Cassidy said Overton had a “viable confirmation path” and that he was “having productive conversations with members” that led him to believe she could be confirmed. He said the key issue that blocked her path forward was resistance from the White House to meet the demands of anti-abortion senators, who have been pushing the administration to further restrict access to abortion pills, which now account for the majority of abortions nationwide.
The FDA is currently reviewing the safety of abortion pills, despite more than 100 scientific studies confirming they are safe and effective. At her confirmation hearing, Overton said the safety study would be a priority, but she also refused to weigh in on the pills’ safety and efficacy when asked by senators on both sides of the issue.
The White House did not immediately respond to a request for comment from MS NOW about Cassidy’s claims.
In addition to Cassidy and other Republicans on the Senate HELP Committee, supporters of HHS Secretary Robert F. Kennedy’s “Make America Healthy Again” initiative also opposed Overton’s nomination, arguing that she would not sufficiently challenge corporate interests.
Semafor first reported on Tuesday that the administration was considering Sen. Roger Marshall, R-Kan., as a replacement for Overton. Marshall, a doctor and member of the committee, lost his re-election bid earlier this month. The administration was seeking to establish a replacement in order to secure a confirmed FDA commissioner before control of Congress flips in the new year, likely making any pick more difficult.
As of Tuesday night, White House officials had not yet named a new nominee to lead the agency of more than 18,000 employees.
Overton has served as a deputy assistant to the president for domestic policy since the start of President Donald Trump’s second term, according to her LinkedIn profile. She previously worked at the America First Policy Institute, a nonprofit conservative think tank, and served as a White House fellow during Trump’s first term, according to her profile. Overton graduated from medical school at the University of New Mexico and holds a doctorate from Johns Hopkins Bloomberg School of Public Health.
She faced tough questions before the Senate Health committee in September, when senators asked her about the FDA’s loosening of food safety regulations, changes to vaccine policy and her opposition to abortion in light of the agency’s ongoing review of the pills, which could lead to restricted access.
Mini Timmaraju, president and CEO of the abortion rights advocacy group Reproductive Freedom For All, welcomed the withdrawal on Tuesday night, saying Overton “posed a serious threat to the future of medication abortion access.”
“If Republicans try to rush through another nominee who threatens our healthcare, we’re ready to keep fighting,” Timmaraju said in a statement.
The previous FDA commissioner, Marty Makary, was in the role from March 2025 until he resigned in May. He recently spoke out against the Trump administration, telling Politico that he witnessed — and rejected — “government corruption.” He also alleged that officials were more focused on “getting more vapes approved and catering to lobbyists” than “medical cures or healthy food.”
In response to Makary’s remarks, White House spokesperson Allison Schuster previously told MS NOW that the “only special interest guiding President Trump’s decision-making is the best interest of the American people” and that “Gold Standard Science” was the “only guiding factor” driving federal health policy.
Since Makary’s departure, Kyle Diamantas, the former deputy commissioner of food, has served as the agency’s acting commissioner.
Ebony Davis contributed to this report.
The post White House withdraws FDA nominee Heidi Overton amid GOP opposition appeared first on MS NOW.
From MS Now.

Leave a Reply